EATG » Theratechnologies announces FDA decision to extend the ibalizumab review period

Theratechnologies announces FDA decision to extend the ibalizumab review period

Theratechnologies Inc. announced that it was notified by its partner, TaiMed Biologics, Inc., that the U.S. Food and Drug Administration will extend its review of the Biologics License Application for ibalizumab. In a notice received today by TaiMed from the FDA, the Prescription Drug User Fee Act target action date has been extended to April 3, 2018.

Read the full press release here.